SCHEDULE 13G/A: Armistice Capital and Steven Boyd Disclose 5.92% Stake in Ironwood Pharmaceuticals

Armistice Capital, LLC and Steven Boyd have jointly disclosed a beneficial ownership of 5.92% of Ironwood Pharmaceuticals Inc.'s Class A common stock, totaling 9,468,000 shares.

Summary

• Armistice Capital, LLC and Steven Boyd, collectively referred to as the 'Reporting Persons', have filed an Amendment No. 1 to Schedule 13G regarding their beneficial ownership in Ironwood Pharmaceuticals Inc.
• As of December 31, 2024, the Reporting Persons beneficially own an aggregate of 9,468,000 shares of Ironwood Pharmaceuticals' Class A common stock.
• This ownership represents 5.92% of the Class A common stock outstanding.
• The percentage is calculated based on 160,028,388 shares outstanding as of October 31, 2024, as reported in the Issuer's Form 10-Q filed on November 7, 2024.
• Armistice Capital, LLC acts as the investment manager for Armistice Capital Master Fund Ltd., which is the direct holder of the shares.
• Steven Boyd, as the managing member of Armistice Capital, is deemed to beneficially own the securities held by the Master Fund.
• The shares were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing the control of the issuer.

Sentiment

Score: 5

Explanation: Neutral. This is a factual disclosure of beneficial ownership and does not contain information that would inherently indicate positive or negative sentiment regarding the company's performance or prospects.

Future Outlook

This document is a beneficial ownership disclosure and does not contain forward-looking statements or guidance regarding the issuer's future performance or outlook.

Industry Context

This filing indicates a significant passive investment by an investment manager and its principal in a pharmaceutical company, which is a common occurrence in the biotech and pharmaceutical sectors where institutional investors often take substantial positions based on drug pipelines, market potential, and financial health.

Stakeholder Impact

• Shareholders: The disclosure of a significant beneficial owner can provide transparency regarding the company's ownership structure and potentially influence investor perception of institutional interest in the stock.

Key Dates

Keywords

Ironwood Pharmaceuticals, Armistice Capital, Steven Boyd, Schedule 13G, Beneficial Ownership, Class A Common Stock, Pharmaceuticals, Investment Management, SEC Filing